WO2001064650A3 - Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues - Google Patents

Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues Download PDF

Info

Publication number
WO2001064650A3
WO2001064650A3 PCT/US2001/006643 US0106643W WO0164650A3 WO 2001064650 A3 WO2001064650 A3 WO 2001064650A3 US 0106643 W US0106643 W US 0106643W WO 0164650 A3 WO0164650 A3 WO 0164650A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogues
epothilones
intermediates
synthesis
cancer
Prior art date
Application number
PCT/US2001/006643
Other languages
English (en)
Other versions
WO2001064650A2 (fr
Inventor
Samuel J Danishefsky
Chul Bom Lee
Mark Chappell
Shawn Stachel
Ting-Chao Chou
Original Assignee
Sloan Kettering Inst Cancer
Samuel J Danishefsky
Chul Bom Lee
Mark Chappell
Shawn Stachel
Chou Ting Chao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer, Samuel J Danishefsky, Chul Bom Lee, Mark Chappell, Shawn Stachel, Chou Ting Chao filed Critical Sloan Kettering Inst Cancer
Priority to AU2001243372A priority Critical patent/AU2001243372A1/en
Priority to JP2001563492A priority patent/JP2004500388A/ja
Priority to EP01916335A priority patent/EP1259490A2/fr
Priority to CA002401800A priority patent/CA2401800A1/fr
Publication of WO2001064650A2 publication Critical patent/WO2001064650A2/fr
Publication of WO2001064650A3 publication Critical patent/WO2001064650A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des procédés convergents permettant de préparer des épothilones, des désoxyépothilones et leurs analogues. La présente invention concerne également de nouvelles compositions et de nouveaux procédés pour le traitement du cancer, ainsi que des procédés pour le traitement de cancers développant un phénotype de multirésistance médicamenteuse.
PCT/US2001/006643 2000-03-01 2001-03-01 Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues WO2001064650A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001243372A AU2001243372A1 (en) 2000-03-01 2001-03-01 Synthesis of epothilones, intermediates thereto and analogues thereof
JP2001563492A JP2004500388A (ja) 2000-03-01 2001-03-01 エポチロン、その中間体およびその類似体の合成
EP01916335A EP1259490A2 (fr) 2000-03-01 2001-03-01 Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues
CA002401800A CA2401800A1 (fr) 2000-03-01 2001-03-01 Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18596800P 2000-03-01 2000-03-01
US60/185,968 2000-03-01
US25044700P 2000-11-30 2000-11-30
US60/250,447 2000-11-30

Publications (2)

Publication Number Publication Date
WO2001064650A2 WO2001064650A2 (fr) 2001-09-07
WO2001064650A3 true WO2001064650A3 (fr) 2002-05-10

Family

ID=26881647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006643 WO2001064650A2 (fr) 2000-03-01 2001-03-01 Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues

Country Status (5)

Country Link
EP (1) EP1259490A2 (fr)
JP (1) JP2004500388A (fr)
AU (1) AU2001243372A1 (fr)
CA (1) CA2401800A1 (fr)
WO (1) WO2001064650A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41990E1 (en) 1996-12-03 2010-12-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US8034815B2 (en) 2007-01-11 2011-10-11 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US8895556B2 (en) 2007-12-26 2014-11-25 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9284275B2 (en) 2007-01-11 2016-03-15 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ305799B6 (cs) * 2001-03-14 2016-03-23 Bristol-Myers Squibb Company Kombinace analogů epothilonu a chemoterapeutických činidel pro léčení proliferačních nemocí
JP2006514681A (ja) * 2002-05-20 2006-05-11 コーザン バイオサイエンシス インコーポレイテッド エポチロンｄの投与方法
MXPA04012444A (es) * 2002-06-10 2005-04-19 Novartis Ag Combinaciones que comprenden epotilonas y sus usos farmaceuticos.
AU2003252540B2 (en) * 2002-07-15 2008-11-20 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Novel macrocycles for the treatment of cancer
AR040956A1 (es) 2002-07-31 2005-04-27 Schering Ag Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico
JP2006505627A (ja) * 2002-07-31 2006-02-16 シエーリング アクチエンゲゼルシャフト 新規エフェクター接合体、それらの生成方法及びそれらの医薬使用
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
DE60330407D1 (de) 2002-08-23 2010-01-14 Sloan Kettering Inst Cancer Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
EP1553939A1 (fr) * 2002-10-11 2005-07-20 Dana-Farber Cancer Institute, Inc. Derives epothilone pour le traitement du myelome multiple
JP2005095152A (ja) * 2003-08-29 2005-04-14 Japan Tissue Engineering:Kk 培養組織の保存方法
EP1674098A1 (fr) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Formulations parenterales stables et tolérables des substances de haut réactivité ayant une solubilité basse ou inexistante dans l'eau
EP2065054A1 (fr) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinaisons comprenant une prostaglandine et leurs utilisations
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (fr) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nanoparticules à surface modifiée
EP2210584A1 (fr) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Composition polymère stable comprenant un copolymère séquencé d'épothilone et amphiphile
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
EP2872894B1 (fr) 2012-07-13 2019-04-17 Innate Pharma Criblage d'anticorps conjugués
WO2014072482A1 (fr) 2012-11-09 2014-05-15 Innate Pharma Etiquettes de reconnaissance pour la conjugaison à médiation par la tgase
TWI520956B (zh) * 2013-03-08 2016-02-11 台灣神隆股份有限公司 伊莎匹隆及其中間體之製備方法
EP2968582B1 (fr) 2013-03-15 2020-07-01 Innate Pharma Conjugaison d'anticorps en phase solide médiée par la tgase
EP3010547B1 (fr) 2013-06-20 2021-04-21 Innate Pharma Conjugaison enzymatique de polypeptides
EP3010548A1 (fr) 2013-06-21 2016-04-27 Innate Pharma Conjugaison enzymatique de polypeptides
WO2019092148A1 (fr) 2017-11-10 2019-05-16 Innate Pharma Anticorps avec des résidus de glutamine fonctionnalisés
KR20210150496A (ko) * 2019-04-05 2021-12-10 프로린크스 엘엘시 개선된 컨쥬게이션 링커

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARRIS C R ET AL: "COMPLEX TARGET-ORIENTED SYNTHESIS IN THE DRUG DISCOVERY PROCESS: A CASE HISTORY IN THE DEPOB SERIES", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 64, 1999, pages 8434 - 8456, XP000984318, ISSN: 0022-3263 *
NICOLAOU K C ET AL: "Chemical Biology of Epothilones", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 37, no. 15, August 1998 (1998-08-01), pages 2014 - 2045, XP002131418, ISSN: 0570-0833 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41990E1 (en) 1996-12-03 2010-12-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US8034815B2 (en) 2007-01-11 2011-10-11 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US9284275B2 (en) 2007-01-11 2016-03-15 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US8895556B2 (en) 2007-12-26 2014-11-25 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9422282B2 (en) 2010-04-01 2016-08-23 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV

Also Published As

Publication number Publication date
JP2004500388A (ja) 2004-01-08
AU2001243372A1 (en) 2001-09-12
WO2001064650A2 (fr) 2001-09-07
EP1259490A2 (fr) 2002-11-27
CA2401800A1 (fr) 2001-09-07

Similar Documents

Publication Publication Date Title
WO2001064650A3 (fr) Synthese d'epothilones, de leurs produits intermediaires et de leurs analogues
EP1386922A3 (fr) Synthèse d'épitholones, intermédiaires, analogues et leur utilisation
IL138113A0 (en) Synthesis of epothilones, intermediates thereto and analogues thereof
IL157478A0 (en) Method for the synthesis of 2', 3'-didehydronucleosides
CA2475302A1 (fr) Synthese controlee de ziprasidone et ses compositions
WO2002076976A3 (fr) Inhibiteurs de rho-kinase
WO2004078757A3 (fr) Synthese
PL362715A1 (en) Process for the epoxidation of olefins
MXPA03008041A (es) Proceso para la fabricacion de articulos moldeados.
IL150432A0 (en) Process for the epoxidation of olefins
WO2004032908A3 (fr) Methode d'inhibition de l'angiogenese
IT1317722B1 (it) Procedimento per la produzione di gas di sintesi.
EP1529777A3 (fr) Un procédé et un oxalidine comme intermédiare pour la synthèse des taxanes.
PL362616A1 (en) Process for the epoxidation of olefins
WO2002047604A3 (fr) Utilisation des composes de la classe des chalcones pour inhiber la vascularisation d'une masse tumorale
MXPA02006102A (es) Metodo para preparar compuestos bormodifluoroaceticos.
AU2002330042A1 (en) Process for the preparation of 1,5-diarylpyrazoles
AU2001277728A1 (en) Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
HK1063052A1 (en) A process for the preparation of paclitaxel
WO2002096799A3 (fr) Sous-nitrure de silicium
MXPA03002926A (es) Proceso para la sintesis de 2,2,6,6,-tetrametil-4--oxipiperidina.
MXPA02003042A (es) Proceso para prevenir formacion de incrustaciones.
AU4568301A (en) Process for adjusting the hardness of fischer-tropsch wax by blending
MXPA03009210A (es) PROCEDIMIENTO PARA LA PREPARACIoN DE OXABISPIDINAS.
WO2003005970A3 (fr) Polymorphe de carvedilol

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2401800

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 563492

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001243372

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001916335

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001916335

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642